Testing results received from Pfizer Canada ULC identified 5 lots of CHAMPIX with levels of a nitrosamine impurity,
N-nitrosovarenicline, above the acceptable intake limit established by Health Canada.
N-nitrosovarenicline has been shown to cause gene mutations in an
in vitro study, indicating that its presence in CHAMPIX may be associated with a potential increased cancer risk in humans. Health Canada is informing healthcare professionals about the risk associated with these 5 lots.
Products affected
|
CHAMPIX (varenicline), Pfizer Canada ULC |
|
Strength/Dosage Form |
DIN |
Lot # |
Expiry Date |
Recall Status |
|
0.5 mg and 1 mg Tablet, Kit |
02298309 |
00019062 |
2021-08 |
Recalled |
|
00020452 |
2021-12 |
Recalled |
|
00020451 |
2022-01 |
Recalled |
|
0.5 mg Tablet |
02291177 |
ED7397 |
2022-05 |
Recalled |
|
1 mg Tablet |
02291185 |
00020013 |
2021-12 |
Outstanding |
Background Information
CHAMPIX is a prescription medication indicated for smoking-cessation treatment in adults, in conjunction with smoking-cessation counselling.
N-nitrosovarenicline, a nitrosamine impurity, has been shown to cause gene mutations in an
in vitro study, indicating that its presence in CHAMPIX may be associated with a potential increased cancer risk in humans. However, studies have not been conducted to determine whether exposure to
N-nitrosovarenicline leads to the development of cancer in animals or humans. Some nitrosamine impurities are probable human carcinogens. This means that long-term exposure to a level above what is considered safe could increase the risk of cancer. Health Canada established an acceptable intake limit based on available scientific data.
On October 26, 2020, Health Canada requested all companies marketing varenicline to evaluate the risk of the presence of nitrosamine impurities in their drug product and to conduct testing as necessary.
Testing results received from Pfizer Canada ULC identified 5 lots of CHAMPIX with levels of a nitrosamine impurity,
N-nitrosovarenicline, above the acceptable intake limit established by Health Canada. As a result, Health Canada requested that Pfizer Canada ULC recall the 5 impacted lots to address this safety risk (see Products affected section). CHAMPIX is not considered a medically necessary drug product in Canada, as there are alternative varenicline products on the market.
Health Canada has taken action to address the issue of nitrosamine impurities found in certain medications since the summer of 2018. Health Canada continues to work closely with international regulatory partners and companies to address the issue and will continue to keep Canadians informed. More information on Health Canada's work to address nitrosamines in medications is available on
Canada.ca.